TELIX Pharmaceuticals Ltd - Asset Resilience Ratio

Latest as of June 2018: 32.29%

TELIX Pharmaceuticals Ltd (TLX) has an Asset Resilience Ratio of 32.29% as of June 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of TELIX Pharmaceuticals Ltd to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

AU$15.67 Million

≈ $11.08 Million USD Cash + Short-term Investments

Total Assets

AU$48.51 Million

≈ $34.32 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (None–None)

This chart shows how TELIX Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see TLX asset base.

Liquid Assets Composition Over Time

This chart breaks down TELIX Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore TELIX Pharmaceuticals Ltd (TLX) long-term investment share to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$0.00	0%
Short-term Investments	AU$15.67 Million	32.29%
Total Liquid Assets	AU$15.67 Million	32.29%

Asset Resilience Insights

Very High Liquidity: TELIX Pharmaceuticals Ltd maintains exceptional liquid asset reserves at 32.29% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

TELIX Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio

Compare TELIX Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for TELIX Pharmaceuticals Ltd (None–None)

The table below shows the annual Asset Resilience Ratio data for TELIX Pharmaceuticals Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
No yearly data available.

pp = percentage points

About TELIX Pharmaceuticals Ltd

AU:TLX Australia Biotechnology

Market Cap

$4.20 Billion

AU$5.94 Billion AUD

Market Cap Rank

#4665 Global

#114 in Australia

Share Price

AU$17.75

Change (1 day)

+8.63%

52-Week Range

AU$8.63 - AU$17.75

All Time High

AU$31.14